Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30895047 | 0.93 | MAPK1 (0.39) | GSK3BDYRK1APIK3CAMTORBRD4 | |
| SCHEMBL25753091 | 0.93 | MAPK1 (0.39) | GSK3BDYRK1APIK3CAMTORBRD4 | |
| SCHEMBL30895121 | 0.93 | GSK3B (0.36) | GSK3BDYRK1AGPR119DGAT1PIK3CA | |
| SCHEMBL27199485 | 0.85 | BRD4 (0.38) | BRD4ABL1 | |
| SCHEMBL30860940 | 0.85 | RXRA (0.38) | GSK3BDYRK1ADGAT1BRD4TP53 | |
| SCHEMBL30860930 | 0.84 | GSK3B (0.40) | GSK3BDYRK1APIK3CAPRKDCABL1 | |
| SCHEMBL25756633 | 0.84 | GSK3B (0.40) | GSK3BDYRK1APIK3CAPRKDCABL1 | |
| SCHEMBL31017447 | 0.81 | GSK3B (0.36) | GSK3BDYRK1ADGAT1PIK3CAPRKDC | |
| SCHEMBL30895136 | 0.81 | GSK3B (0.36) | GSK3BDYRK1ADGAT1PIK3CAPRKDC | |
| SCHEMBL25753072 | 0.81 | PIK3CD (0.42) | GSK3BDYRK1APIK3CAPRKDCMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | GSK3B 117/4885DYRK1A 56/4885GPR119 1654/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | GSK3B 117/4885DYRK1A 56/4885GPR119 1654/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | GSK3B 117/4885DYRK1A 56/4885GPR119 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.